Clinical Trials · NCT05210582
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Clinuvel, Inc.
- Enrollment
- 6
- Start date
- Oct 2022
- Locations
- 1 site, United States
- Primary endpoint
- Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions